Table 1.
Demographics, survival, study site and combined TERT/ATRX status by integrated 2016 WHO glioma entities.
| 2016 WHO Group | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| All | Group 1 ligodendroglioma, IDH-mutant and 1p/19q-codeleted |
Group 2 Astrocytoma, IDH-mutant |
Group 3 Glioblastoma, IDH-mutant |
Group 4 Glioblastoma, IDH-wildtype |
Group 5 Astrocytoma, IDH-wildtype |
|
| Total | 1206 | 291 | 401 | 51 | 309 | 154 |
|
| ||||||
| Age mean (median) | 47 (46) | 45 (44) | 38 (36) | 42 (38) | 59 (59) | 50 (52) |
| Male gender n (%) | 722 (60%) | 167 (57%) | 243 (61%) | 36 (71%) | 192 (62%) | 84 (55%) |
| Percent deceased | 45% | 19% | 30% | 67% | 81% | 57% |
| Median survival (years) | 5.3 | 17.5 | 9.3 | 3.6 | 1.2 | 1.9 |
| Study Site | ||||||
| UCSF | 347 (29%) | 86 (30%) | 116 (29%) | 17 (33%) | 76 (25%) | 52 (34%) |
| Mayo | 296 (25%) | 68 (23%) | 87 (22%) | 25 (49%) | 97 (31%) | 19 (12%) |
| TCGA | 563 (47%) | 137 (47%) | 198 (49%) | 9 (18%) | 136 (44%) | 83 (54%) |
| TERT/ATRX | ||||||
| WT/WT | 187 (16%) | 11 (4%) | 63 (16%) | 10 (20%) | 60 (19%) | 43 (28%) |
| WT/MUT | 371 (31%) | 2 (1%) | 311 (78%) | 32 (63%) | 10 (3%) | 16 (10%) |
| MUT/WT | 629 (52%) | 273 (94%) | 20 (5%) | 6 (12%) | 238 (77%) | 92 (60%) |
| MUT/MUT | 19 (2%) | 5 (2%) | 7 (2%) | 3 (6%) | 1 (0%) | 3 (2%) |
| TERT-MUT n (column %) | 648 (54%) | 278 (96%) | 27 (7%) | 9 (18%) | 239 (77%) | 95 (62%) |
| ATRX-MUTa n (column %) | 390 (32%) | 7 (2%) | 318 (79%) | 35 (69%) | 11 (4%) | 19 (12%) |
a
UCSF and Mayo Clinic cases has ATRX alterations identified by immunohistochemistry while TCGA cases had ATRX alterations identified by sequencing. ATRX alterations were found in 36% of UCSF cases, 35% of Mayo cases and 28% of TCGA cases.